Professor Kevin Brindle and Professor Alan Jackson
Established in 2013, the CRUK and EPSRC Cancer Imaging Centre at Cambridge and Manchester combines a wealth of imaging expertise and experience to develop the tools necessary to improve the diagnosis, monitoring and treatment of cancer.
Cambridge is one of the world leaders in the application of hyperpolarised 13C magnetic resonance (MR) imaging to oncology and is at the forefront of the development of novel targeted imaging probes - for example in the early detection of dysplasia using fluorescence endoscopy and detection of cell death using a targeted imaging probe. Manchester is known as a leading centre for the development and application of advanced MR imaging and image analysis techniques, particularly applied to tumour phenotyping, drug development and early phase drug trials.
We bring together emerging imaging methods using state-of-the-art equipment with novel chemical and biochemical approaches and aim to rapidly translate new agents and technologies from the laboratory into the clinic in order to impact patient care. Through our partnerships with pharmaceutical companies, we run pioneering clinical studies to examine how imaging is able to guide therapy and inform clinical outcomes. Multimodality trials integrate imaging with circulating and tissue biomarkers for a more comprehensive view of tumour biology and therapeutic response.
An essential part of the Centre is developing the cancer imaging scientists and clinicians of the future. Our training programme provides the opportunity for those with a background in biology, chemistry, physics, engineering and medicine to undertake both clinical and non-clinical doctoral studies in cancer imaging.
The establishment of the CRUK and EPSRC Cancer Imaging Centre at Cambridge and Manchester recognises our ambition to become an international centre of excellence in cancer imaging and to provide innovative approaches that benefit cancer patients.